Display options
Cite
Gralow I, von Hornstein WF, Schleyer E, et al. Kontinuierliche subkutane Buprenorphinapplikation in der Therapie karzinombedingter Schmerzen. [Continuous subcutaneous buprenorphine application in the treatment of cancer pain.]. Schmerz. 1995;9(3):117-23doi: 10.1007/BF02530129.
Gralow, I., von Hornstein, W. F., Schleyer, E., & Hiddemann, W. (1995). Kontinuierliche subkutane Buprenorphinapplikation in der Therapie karzinombedingter Schmerzen. [Continuous subcutaneous buprenorphine application in the treatment of cancer pain.]. Schmerz (Berlin, Germany), 9(3), 117-23. https://doi.org/10.1007/BF02530129
Gralow, I, et al. "Kontinuierliche subkutane Buprenorphinapplikation in der Therapie karzinombedingter Schmerzen." [Continuous subcutaneous buprenorphine application in the treatment of cancer pain.]. Schmerz (Berlin, Germany) vol. 9,3 (1995): 117-23. doi: https://doi.org/10.1007/BF02530129
Gralow I, von Hornstein WF, Schleyer E, Hiddemann W. Kontinuierliche subkutane Buprenorphinapplikation in der Therapie karzinombedingter Schmerzen. [Continuous subcutaneous buprenorphine application in the treatment of cancer pain.]. Schmerz. 1995 May;9(3):117-23. doi: 10.1007/BF02530129. German. PMID: 18415545.
Copy Download .nbib Format: NLM
Share it on

Schmerz. 1995 May;9(3):117-23. doi: 10.1007/BF02530129.

[Continuous subcutaneous buprenorphine application in the treatment of cancer pain.].

Schmerz (Berlin, Germany)

[Article in German]
I Gralow, W F von Hornstein, E Schleyer, W Hiddemann

Affiliations

  1. Schmerzambulanz und Tagesklinik der Klinik und Poliklinik für Anästhesiologie und operative Intensivmedizin der Westfälischen Wilhelms-Universität Münster, Albert-Schweitzer-Straße 33, D-48129, Münster.

PMID: 18415545 DOI: 10.1007/BF02530129

Abstract

Introduction Buprenorphine is well known in cancer pain therapy because of the long duration of its action and high analgesic potency. Many studies exist about the intravenous and sublingual application form; however, few data are available on its use by the continuous subcutaneous route. Methods Twenty-five patients were analysed retrospectively over 956 days who has been treated with continuous subcutaneous buprenorphine for cancer-related pain. In 7 of these 25 patients plasma analyses were performed. Due to a modified sensitive HPLC method with electrochemical detection for the analysis of buprenorphine in plasma, a detection limit of 40 pg/ml could be obtained. The other analytical methods for plasma concentration have detection limits between 150 and 500 pg/ml. Results During the treatment with continuous subcutaneous buprenorphine it was necessary to increase the initial average daily dose of 1.07 (+/-0.41) mg to 1.58 (+/-0.58) mg. The initially high pain intensity (rated from 0 to 100%) of 67% could be reduced to a moderate pain of 26% on average. Only 2 patients had to be switched over to morphine because of insufficient analgesia. In no case did complications occur that required intervention or would have made it necessary to change the pain therapy. Eighty percent of the patients judged this kind of treatment as effective and comfortable. Most often patients complained about drowsiness, low appetite and constipation. Because of the progress of the cancer disease these effects could not clearly be related to treatment side effects. With 7 of 25 patients the median daily dose of 1.2 (minimum 0.9-maximum 2.3) mg buprenorphine was related to the median plasma concentration of 438 (minimum 64-maximum 3374) pg/ml. In one case with progressive liver dysfunction, the potential risk of cumulation with buprenorphine could be controlled with this method. Conclusions Continuous subcutaneous buprenorphine with external infusors is a safe and efficient cancer pain therapy without severe side effects. Because of its ceiling effect, it is not as effective as morphine, but can be discussed as an alternative if other opioids cause incompatibility reactions.

References

  1. J Chromatogr. 1985 Feb 27;338(1):89-98 - PubMed
  2. Clin Ther. 1982;5(1):61-8 - PubMed
  3. Hiroshima J Med Sci. 1985 Sep;34(3):261-5 - PubMed
  4. Clin J Pain. 1989 Jun;5(2):147-52 - PubMed
  5. J Pharm Biomed Anal. 1987;5(3):303-8 - PubMed
  6. Br J Anaesth. 1985 Feb;57(2):192-6 - PubMed
  7. Br J Clin Pharmacol. 1981 Aug;12(2):117-22 - PubMed
  8. Clin Pharmacol Ther. 1980 Nov;28(5):667-72 - PubMed
  9. J Pharm Pharmacol. 1988 Sep;40(9):666-7 - PubMed
  10. J Chromatogr. 1993 May 5;614(2):275-83 - PubMed
  11. J Chromatogr. 1989 Feb 24;487(2):469-75 - PubMed
  12. Naunyn Schmiedebergs Arch Pharmacol. 1988 Aug;338(2):202-6 - PubMed
  13. Clin Pharmacol Ther. 1988 Sep;44(3):335-42 - PubMed
  14. Cancer Treat Rep. 1987 Jun;71(6):635-7 - PubMed
  15. Br J Clin Pharmacol. 1982 May;13(5):665-73 - PubMed
  16. Clin Pharmacokinet. 1983 Jul-Aug;8(4):332-43 - PubMed
  17. Arch Gen Psychiatry. 1978 Apr;35(4):501-16 - PubMed
  18. Anaesthesist. 1983 Dec;32(12):601-9 - PubMed
  19. Drug Metab Dispos. 1984 Sep-Oct;12(5):577-81 - PubMed
  20. Schmerz. 1987 Jul;1(1):48-51 - PubMed
  21. Anesth Analg. 1989 Mar;68(3):377-84 - PubMed
  22. Schmerz. 1988 Mar;2(1):38-41 - PubMed
  23. Drugs. 1979 Feb;17(2):81-110 - PubMed
  24. Schmerz. 1993 Mar;7(1):31-9 - PubMed

Publication Types